Tag Archives: biotech

RESI Healthtech Week, September 5th thru 7th

19 Jul

Day 1 Spotlight: 6 Premier Early Stage Tech Hubs Attending The First Coast Innovator’s Gathering

By Ashley Durrer, Marketing Manager, LSN

The First Coast Innovator’s Gathering on Day 1 is focused on tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. We encourage all global tech hubs and their constituents to attend.

Tech hubs and global attendees will be able to sign up for partnering meetings ahead of the conference, making sure they setup ideal meetings with global investors and strategic partners that are a fit for their technology and stage of development. Tech hub members are also eligible to apply for free to the First Coast Innovation Challenge to pitch in front of a panel of investors. The deadline to apply for the Innovation Challenge is July 27, 2018. These tech hub programs represent a microscopic portion of the unbelievable innovation and talent spinning out of the northeast corridor, within life sciences from Biotech, Medtech, Diagnostics, Therapeutics, and Digital Health.

The highlighted tech hubs shared their goals for attending.


Richard Bendis, President and CEO at BioHealth Innovation Inc.

“BHI is excited to support the inaugural First Coast Innovator’s Gathering as we need to leverage all the assets within the First Coast Region in order to find new ways to collaborate more effectively.”


About BioHealth Innovation Inc.

The BioHealth Capital Region has unmatched biohealth assets from iconic federal institutions, world-class universities, top-notch healthcare facilities, and global and emerging bioscience companies. However, we have yet to fully realize the return on investment from these assets. This is largely due to the lack of a cohesive strategy in moving ideas from labs to the market. While other regions with far fewer assets have proactively addressed this opportunity by creating innovation-driven economic development organizations and initiatives. It is time central Maryland started to close this gap, and it is BioHealth Innovation’s mission to complete.



William Brah, Director at UMass Venture Development Center

“We go out of our way to facilitate visas for international students creating life science companies in Massachusetts, bringing an international audience to the industry.

Several life science companies from our incubator successfully connected with investors through the RESI Conference and LSN Investor Database. We continue to encourage our members to broaden their investor target list to include investors all around the world who attend regular RESI Conferences—just as we bring in international students.”

About UMass Venture Development Center

UMass Venture Development Center focuses on early-stage high tech companies within life sciences with more than half specialized in biotech, medical devices, diagnostics, therapeutics, and digital health. Typical company candidates include companies at the seed stage. They are supported through Series A funding rounds. and help them through series A. Recent success stories include the acquisition of a local Massachusetts startup called PillPack by Amazon and a multiple million-dollar deal between Roche and SQZ Biotechnologies.


Mary Ann Picard, Director of Operations at M2D2@UMass

“Picard shared her goals are “to continually increase awareness of our program and the amazing inventions being incubated. We strive to match our early stage resident companies with university resources, strategic partners and investors interested in their technologies. With the deep capabilities available at UMass Lowell and the UMass Medical School, we do all we can to help the startups be successful.”

About M2D2@UMass

Massachusetts Medical Device Development Center (M2D2) is an incubator program, a joint project between UMass Lowell and the UMass Medical School, focused on medical device and biotech innovations. No affiliation with UMass is required for early-stage life science startups to take advantage of the M2D2 program.


Todd Keiller, Director of Intellectual Property and Innovation at Worchester Polytechnic Institute





About Worchester Polytechnic Institute (WPI)

Worchester Polytechnic Institute helps innovators learn to explore problems and solutions from many directions and, along the way, experience the multiplying effect of one great mind upon another.


Russ Yukhananov, Founder and President at Mansfield Bio-Incubator Inc.

“We provide a collaborative environment to help ensure entrepreneurs’ success in realizing their dreams and growing the next generation of biotechnology companies. They are encouraged to move forward through access to a laboratory, mentoring program that helps to develop a business plan, connections with investors, and the supporting environment for product development.

We’re excited to establish new relationships with global investors and emerging startups at the RESI Conference who are involved in life science innovations.”

About Mansfield Bio-Incubator Inc.

Mansfield Bio-Incubator is a non-profit biotech, pharma, life science, and medical device business incubator facility. Our mission is to facilitate and assist the creation, growth, and success of the next generation of biotech, pharma, life science, and medical device companies.  We were created to nurture entrepreneurial and economic development in the community. We aim to do this by maintaining an affordable lab and office space and making cutting-edge technology, services, training, mentoring, and a network of professional advisors available to small biotechnology companies and healthcare-related start-ups.


New York City

Annette Baker, President and Business Development at CTF





About the Children’s Tumor Foundation (CTF)

Our vision is to end Neurofibromatosis (NF). The Children’s Tumor Foundation’s mission is to drive research, expand knowledge, and advance care for the NF community. Since its formation, the Children’s Tumor Foundation has been crucial to the development of solid scientific data about the genetic disorder neurofibromatosis (NF). Thanks to the generosity of our donors and supporters, we are breaking through barriers and forging the pathway that will lead to a cure.



RESI Healthtech Week is being sponsored by J&J Innovation, Stetson Family Office, and Big3Bio.

China Investment Firm Seeks Novel Oncology/First-In-Class Therapeutic Drugs and Diagnostics

19 Jul

A biotech incubator sector fund founded in 2015 is headquartered in China with an additional USA office. The firm currently manages two venture funds including an RMB and USD fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 6-8 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in oncology-related small molecule drugs and first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices or Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: